Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
Neuro-Oncology Advances · 01.01.2023 · 5 (1)
DOI: 10.1093/noajnl/vdad012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 14.02.2023. Verfasst von Mirjam Renovanz und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Germa…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: German Scholars Organization, Else Kröner Forschungskolleg Tübingen, Medical Faculty Tübingen.
Abstract (Originalsprache)
Background
The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the nervous system within a prospective observational study. Methods molecular tumor board (MTB)@ZPM (NCT03503149) is a prospective observational precision medicine study for patients with advanced tumors. After inclusion of patients, we performed comprehensive molecular profiling, formulated ranked biomarker-guided therapy recommendations based on consensus by the MTB, and collected prospective clinical outcome data.
Results
Here, we present initial data of 661 adult patients with tumors of the nervous system enrolled by December 31, 2021. Of these, 408 patients were presented at the MTB. Molecular-instructed therapy recommendations could be made in 380/408 (93.1%) cases and were prioritized by evidence levels. Therapies were initiated in 86/380 (22.6%) cases until data cutoff. We observed a progression-free survival ratio >1.3 in 31.3% of patients.
Conclusions
Our study supports the clinical utility of biomarker-guided therapies for neuro-oncology patients and indicates clinical benefit in a subset of patients. Our data might inform future clinical trials, translational studies, and even clinical care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Germany.
- Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Germany.
- Department of Neurosurgery, Eberhard Karls University Tübingen, Germany.
- Center for Personalized Medicine Tübingen, Eberhard Karls University Tübingen, Germany.
- German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Eberhard Karls University of Tübingen, Germany.
- Department of Radiation Oncology, Eberhard Karls University Tübingen, Germany.
ORCID-Profile: Falko Fend, Sara Yvonne Brucker, Oliver Kohlbacher, Sven Nahnsen, Jens Schittenhelm, Ghazaleh Tabatabai
Förderung
- German Scholars Organization
- Else Kröner Forschungskolleg Tübingen
- Medical Faculty Tübingen
Zitieren
APA
Renovanz, M., Kurz, S. C., Rieger, J., Walter, B., Becker, H., Hille, H., Bombach, P., Rieger, D., Grosse, L., Häusser, L., Skardelly, M., Merk, D. J., Paulsen, F., Hoffmann, E., Gani, C., Neumann, M., Beschorner, R., Rieß, O., Roggia, C., …, & Tabatabai, G. (2023). Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad012
Vancouver
Renovanz M, Kurz SC, Rieger J, Walter B, Becker H, Hille H, et al. Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system. Neuro-Oncology Advances. 2023;5(1). doi:10.1093/noajnl/vdad012
BibTeX
@article{Renovanz2023,
author = {Renovanz, Mirjam and Kurz, Sylvia C and Rieger, Johannes and Walter, Bianca and Becker, Hannes and Hille, Hanni and Bombach, Paula and Rieger, David and Grosse, Lucia and Häusser, Lara and Skardelly, Marco and Merk, Daniel J and Paulsen, Frank and Hoffmann, Elgin and Gani, Cihan and Neumann, Manuela and Beschorner, Rudi and Rieß, Olaf and Roggia, Cristiana and Schroeder, Christopher and Ossowski, Stephan and Armeanu-Ebinger, Sorin and Gschwind, Axel and Biskup, Saskia and Schulze, Martin and Fend, Falko and Singer, Stephan and Zender, Lars and Lengerke, Claudia and Brucker, Sara Yvonne and Engler, Tobias and Forschner, Andrea and Stenzl, Arnulf and Kohlbacher, Oliver and Nahnsen, Sven and Gabernet, Gisela and Fillinger, Sven and Bender, Benjamin and Ernemann, Ulrike and Öner, Öznur and Beha, Janina and Malek, Holly Sundberg and Möller, Yvonne and Ruhm, Kristina and Tatagiba, Marcos and Schittenhelm, Jens and Bitzer, Michael and Malek, Nisar and Zips, Daniel and Tabatabai, Ghazaleh},
title = {Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system},
journal = {Neuro-Oncology Advances},
year = {2023},
volume = {5},
number = {1},
doi = {10.1093/noajnl/vdad012}
}
EUVIMED